Two phase III clinical trials proceeded with MAGE-A3 + AS15 for melanoma and non-small-cell lung cancer, but both have been terminated, as MAGE-A3 + AS15 was not efficacious and did not increase disease-free survival compared with the placebo (Table 2). Here, MAGEA3 is linked to non-small cell lung carcinoma.